Hereditary Haemorrhagic Telangiectasia (HHT-WG)

Clinical Trials/Observational Studies

The SAIPAN-trial is a multicenter, randomized, open-label, parallel group, superiority trial aimed at evaluating the effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding. The SAIPAN-trial brings together healthcare professionals from Denmark, France, Italy, and the Netherlands. It is currently ongoing and started since 2021.

Skip to content